SG11201907324VA - Method for preventing or treating autism spectrum disorders by benzoic acid salt - Google Patents

Method for preventing or treating autism spectrum disorders by benzoic acid salt

Info

Publication number
SG11201907324VA
SG11201907324VA SG11201907324VA SG11201907324VA SG11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA
Authority
SG
Singapore
Prior art keywords
international
preventing
benzoic acid
acid salt
treating
Prior art date
Application number
SG11201907324VA
Inventor
Yang Pin-Chen
Lane Hsien-Yuan
Original Assignee
Excelsior Pharmatech Labs
Hsien Yuan Lane
Ying Tung Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63370205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201907324V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Excelsior Pharmatech Labs, Hsien Yuan Lane, Ying Tung Lee filed Critical Excelsior Pharmatech Labs
Publication of SG11201907324VA publication Critical patent/SG11201907324VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT oimiolo VIII °nolo VIII ioo no Elul° oimIE (10) International Publication Number WO 2018/160055 Al (51) International Patent Classification: A61K 31/192 (2006.01) A61P 25/28 (2006.01) A61K 31/196 (2006.01) A61P 43/00 (2006.01) A61P 25/18 (2006.01) (21) International Application Number: PCT/MY2018/000001 (22) International Filing Date: 04 January 2018 (04.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/466,749 03 March 2017 (03.03.2017) US (71) Applicants: EXCELSIOR PHARMATECH LABS [CN/CN]; 14F-7, No. 3, Park St., Nangang Dist., Taipei, Taiwan 11503 (CN). YING-TUNG, Lee [MY/MY]; 8, Jalan Bukit Permai 1/3, Taman Bukit Permai, Bandar Sun- gai Long, Selangor, 43000 (MY). (72) Inventor; and (71) Applicant: HSIEN-YUAN, Lane [CN/CN]; 12F-5, No.360, Jianxing Rd., North Dist., Taichung, 404 (TW). (72) Inventor: PIN-CHEN, Yang; No. 100, Tzyou 1st Road, Kaohsiung, 807 (TW). (74) Agent: JUSTIN, Anandan Santiago; Nanyang IP Sdn Bhd, 30-3, Jalan Bangsar Utama 1, Bangsar, Kuala Lumpur, 59000 (MY). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) as to non prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v)) Published: with international search report (Art. 21(3)) O O (54) Title: METHOD FOR PREVENTING OR TREATING AUTISM SPECTRUM DISORDERS BY BENZOIC ACID SALT 00 (57) : The present disclosure provides a method for preventing or treating an autism spectrum disorder in a subject in need O thereof. The method includes administering to the subject a composition containing a therapeutically effective amount of a benzoic acid salt and a pharmaceutically acceptable excipient thereof. Also provided is a composition for use in preventing or treating an autism C spectrum disorder in a subject in need thereof.
SG11201907324VA 2017-03-03 2018-01-04 Method for preventing or treating autism spectrum disorders by benzoic acid salt SG11201907324VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762466749P 2017-03-03 2017-03-03
PCT/MY2018/000001 WO2018160055A1 (en) 2017-03-03 2018-01-04 Method for preventing or treating autism spectrum disorders by benzoic acid salt

Publications (1)

Publication Number Publication Date
SG11201907324VA true SG11201907324VA (en) 2019-09-27

Family

ID=63370205

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907324VA SG11201907324VA (en) 2017-03-03 2018-01-04 Method for preventing or treating autism spectrum disorders by benzoic acid salt

Country Status (10)

Country Link
US (1) US10987327B2 (en)
JP (1) JP6940631B2 (en)
KR (1) KR102272280B1 (en)
AU (1) AU2018227291B2 (en)
CA (1) CA3054679C (en)
DE (1) DE212018000171U1 (en)
MY (1) MY198069A (en)
SG (1) SG11201907324VA (en)
TW (1) TWI681771B (en)
WO (1) WO2018160055A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114081875A (en) * 2021-11-25 2022-02-25 南京医科大学 New application of sodium benzoate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
TWI455712B (en) * 2010-01-19 2014-10-11 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
US20150265559A1 (en) 2014-03-19 2015-09-24 Kaohsiung Chang Gung Memorial Hospital of the C.G.M.F. Benzoates for use in treating dementia
AU2014386718B8 (en) 2014-03-24 2017-12-07 China Medical University Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment

Also Published As

Publication number Publication date
TW201832763A (en) 2018-09-16
JP2020511530A (en) 2020-04-16
MY198069A (en) 2023-07-31
WO2018160055A1 (en) 2018-09-07
US20200061005A1 (en) 2020-02-27
CA3054679A1 (en) 2018-09-07
TWI681771B (en) 2020-01-11
KR20190117601A (en) 2019-10-16
US10987327B2 (en) 2021-04-27
WO2018160055A8 (en) 2019-11-14
CA3054679C (en) 2021-09-07
KR102272280B1 (en) 2021-07-06
AU2018227291A1 (en) 2019-09-12
AU2018227291B2 (en) 2021-02-11
JP6940631B2 (en) 2021-09-29
DE212018000171U1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201906222WA (en) Jak1 selective inhibitors
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201809561WA (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
SG11201901070YA (en) Formulations for oral administration of active agents
SG11201810618QA (en) Depot formulations
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea